Allianz Asset Management
MRSN

Allianz Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Allianz Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,620
Closed -$372K – 2229
2023
Q1 		$372K Buy
3,620
+1,216
+51% +$171K ﹤0.01% 1953
2022
Q4 		$352K Hold
2,404
– – ﹤0.01% 1791
2022
Q3 		$406K Sell
2,404
-7,005
-74% -$1.14M ﹤0.01% 1558
2022
Q2 		$1.09M Buy
9,409
+1,068
+13% +$100K ﹤0.01% 1647
2022
Q1 		$832K Sell
8,341
-2,634
-24% -$308K ﹤0.01% 1941
2021
Q4 		$1.71M Buy
10,975
+1,677
+18% +$326K ﹤0.01% 1667
2021
Q3 		$2.19M Sell
9,298
-2,040
-18% -$596K ﹤0.01% 1628
2021
Q2 		$3.85M Buy
11,338
+59
+0.5% +$22.3K ﹤0.01% 1228
2021
Q1 		$4.56M Buy
11,279
+2,122
+23% +$1.03M ﹤0.01% 1111
2020
Q4 		$6.09M Sell
9,157
-293
-3% -$163K 0.01% 984
2020
Q3 		$4.4M Buy
9,450
+3,801
+67% +$1.92M 0.01% 1026
2020
Q2 		$3.3M Buy
+5,649
New +$1.93M ﹤0.01% 1381
2019
Q3 		– Sell
-2,090
Closed -$212K – 2773
2019
Q2 		$212K Buy
2,090
+43
+2% +$5.07K ﹤0.01% 2594
2019
Q1 		$269K Buy
2,047
+1,181
+136% +$149K ﹤0.01% 2510
2018
Q4 		$88K Sell
866
-959
-53% -$152K ﹤0.01% 2563
2018
Q3 		$456K Sell
1,825
-800
-30% -$268K ﹤0.01% 2398
2018
Q2 		$1.17M Hold
2,625
– – ﹤0.01% 2171
2018
Q1 		$1.03M Sell
2,625
-659
-20% -$260K ﹤0.01% 2198
2017
Q4 		$1.35M Hold
3,284
– – ﹤0.01% 2144
2017
Q3 		$1.42M Buy
+3,284
New +$1.29M ﹤0.01% 2125

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Allianz Asset Management's MRSN Position: Q2 2023 in Review

Allianz Asset Management sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 3,620 shares — an estimated $372K sold.

Allianz Asset Management first reported a position in MRSN in Q3 2017 and held it in 20 quarters. The position peaked at $6.09M in Q4 2020. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Allianz Asset Management reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Allianz Asset Management sold 3,620 Mersana Therapeutics shares in Q2 2023, an estimated $372K.
  • Allianz Asset Management first reported a position in Mersana Therapeutics in Q3 2017 and held it in 20 quarters.
  • Allianz Asset Management's Mersana Therapeutics position peaked at $6.09M in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Allianz Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.